Aptevo Therapeutics reports strong remission rates in AML patients using mipletamig plus ven/aza, with Cohort 2 enrollment ...

Symptomatic cerebral cavernous malformation is a rare disease, and affected individuals are at risk of strokes due to intracerebral haemorrhage or new non-haemorrhagic neurological deficits.

In this trial, the efficacy and safety of the therapy were evaluated against a sham control in treatment-naïve SMA Type 2 ...

In an early-stage clinical trial, the therapy nearly doubled the expected survival time of young patients. Still, experts ...

Polen Capital, an investment management company, released its “Polen Global Growth Strategy” fourth-quarter 2024 investor ...

Current FDA approval of this adaptive system is for the treatment of Parkinson’s only, not essential tremor, dystonia (a ...

Updated results from the CheckMate 274 trial provide support for adjuvant nivolumab as a standard of care for muscle-invasive bladder cancer, according to Matthew Milowsky, MD.

Nevro Corp. (NYSE:NVRO – Get Free Report ... shares of the medical equipment provider’s stock valued at $816,000 after purchasing an additional 62,568 shares during the last quarter.

Total U.S. permanent implant procedures declined 7% year over year, while U.S. trial procedures decreased 14.2% year over year. During the fourth quarter of 2024, Nevro made significant ...

Management uses certain non-GAAP financial measures, most specifically adjusted EBITDA, as a supplement to GAAP financial measures to further evaluate the Company's operating performance period ...